Cargando…

HLA ligandome tumor antigen discovery for personalized vaccine approach

Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rammensee, Hans-Georg, Singh-Jasuja, Harpreet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821395/ https://www.ncbi.nlm.nih.gov/pubmed/24090147 http://dx.doi.org/10.1586/14760584.2013.836911

Ejemplares similares

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
por: Peper, Janet Kerstin, et al.
Publicado: (2015)

The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination
por: Mühlenbruch, Lena, et al.
Publicado: (2023)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*
por: Mylonas, Roman, et al.
Publicado: (2018)

Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand
por: Fritsche, Jens, et al.
Publicado: (2021)

The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02
por: Mukherjee, Soumya, et al.
Publicado: (2021)

Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity
por: Mommen, Geert P. M., et al.
Publicado: (2016)

Tumour‐associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles
por: Kumar, Pankaj, et al.
Publicado: (2022)

‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization
por: Müller, Markus, et al.
Publicado: (2017)

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome
por: Chong, Chloe, et al.
Publicado: (2018)

Targeting the MHC Ligandome by Use of TCR-Like Antibodies
por: Høydahl, Lene Støkken, et al.
Publicado: (2019)

Pre-fractionation Extends but also Creates a Bias in the Detectable HLA Class Ι Ligandome
por: Demmers, Laura C., et al.
Publicado: (2019)

What Is the Role of HLA-I on Cancer Derived Extracellular Vesicles? Defining the Challenges in Characterisation and Potential Uses of This Ligandome
por: Boyne, Caitlin, et al.
Publicado: (2021)

Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft
por: Kampstra, Arieke S.B., et al.
Publicado: (2019)

Personalized HLA typing leads to the discovery of novel HLA alleles and tumor‐specific HLA variants
por: Anzar, Irantzu, et al.
Publicado: (2022)

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
por: Tegeler, Christian M., et al.
Publicado: (2022)

Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens
por: Nelde, Annika, et al.
Publicado: (2022)

Cross-Presentation of Glycoprotein 96–Associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis
por: Singh-Jasuja, Harpreet, et al.
Publicado: (2000)

Human Histocompatibility Leukocyte Antigen (HLA)-G Molecules Inhibit NKAT3 Expressing Natural Killer Cells
por: Münz, Christian, et al.
Publicado: (1997)

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
por: Walter, Steffen, et al.
Publicado: (2013)

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors
por: Overwijk, Willem W, et al.
Publicado: (2013)

State of the Art in Tumor Antigen and Biomarker Discovery
por: Even-Desrumeaux, Klervi, et al.
Publicado: (2011)

The Peptide Vaccine of the Future
por: Nelde, Annika, et al.
Publicado: (2021)

Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine
por: Gülbakan, Basri, et al.
Publicado: (2016)

Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms
por: Alarcon, Neftali Ortega, et al.
Publicado: (2022)

Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
por: Haen, Sebastian P., et al.
Publicado: (2020)

Recent Advances in Tick Antigen Discovery and Anti-Tick Vaccine Development
por: Abbas, Muhammad Nadeem, et al.
Publicado: (2023)

Melanoma and Human Leukocyte Antigen (HLA): Immunogenicity of 69 HLA Class I Alleles With 11 Antigens Expressed in Melanoma Tumors
por: Georgopoulos, Apostolos P, et al.
Publicado: (2023)

Human Leukocyte Antigen (HLA) Class I Restricted Epitope Discovery in Yellow Fewer and Dengue Viruses: Importance of HLA Binding Strength
por: Lund, Ole, et al.
Publicado: (2011)

Cell Surface B2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA?
por: Ravindranath, Mepur H., et al.
Publicado: (2023)

Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development
por: Fu, Jiantao, et al.
Publicado: (2022)

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process
por: Feola, Sara, et al.
Publicado: (2020)

Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2021)

Discovery and characterization of actionable tumor antigens
por: Ehx, Grégory, et al.
Publicado: (2019)

Correction: Human Leukocyte Antigen (HLA) Class I Restricted Epitope Discovery in Yellow Fewer and Dengue Viruses: Importance of HLA Binding Strength
por: Lund, Ole, et al.
Publicado: (2011)

A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients
por: Gallou, Catherine, et al.
Publicado: (2016)

Malaria vaccines: high-throughput tools for antigens discovery with potential for their development
por: Céspedes, Nora, et al.
Publicado: (2013)

Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse
por: Rijensky, Nataly Mancette, et al.
Publicado: (2020)

Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines
por: Ravindranath, Mepur H., et al.
Publicado: (2022)

Tumor Antigenicity and Approaches to Tumor Immunotherapy
por: Hewitt, H. B.
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_rdq3n0rt1hfgieb7d5d7jv694k